

1

Antimicrobial and Antibiofilm Activities of a Bismuth Lipophilic Nanoparticles Hydrogel against Methicillin-resistant Staphylococcus aureus biofilm

Rene Hernández-Delgadillo¹, Erika Cecilia Espinoza-Villarreal¹, Casiano Del Angel-Mosqueda¹, Osvelia Esmeralda Rodríguez-Luis¹ and Claudio Cabral-Romero¹

¹Universidad Autónoma de Nuevo León, UANL, Facultad de Odontología, Laboratorio de Biología Molecular, Monterrey, Nuevo León, México

Outline

Introduction.....	2
Antimicrobial and antibiofilm activities of BisBAL NPs-Gel on MRSA	4
Characterization of the BisBAL NPs-Gel by SEM	5
Determination of MIC of BisBAL NPs-Gel on MRSA growth	6
Antibiofilm activity of BisBAL NPs-Gel on MRSA biofilm	7
Cytotoxicity of BisBAL NPs-Gel on Human Gingival Fibroblasts (HGFs).....	9
Conclusion.....	9
References.....	10

Introduction

Despite of continuous effort by pharmaceutical industry and medicine, the multidrug resistance among pathogen microorganisms against most common antibiotics has increased drastically. Multidrug resistance has become one of most important health problems worldwide. Nosocomial infections caused by multidrug resistant microorganisms are hard to treat, since 70% of these microbes are resistant against most common drugs. *Staphylococcus aureus* is a pathogen identifies as the etiological agent of health-care-associated infections and community acquired ones¹ (Figure 1.1). The clinical relevance of *S. aureus* infections is due to their resistance to common antibiotics specifically to methicillin (methicillin-resistant *S. aureus*, MRSA)². The infections caused by *S. aureus* community acquired have been increased in the last two years with 50% of these infections caused by MRSA. The strain USA-300 has been recognized as an etiology of osteomyelitis³. Their therapeutic management is a cost driver in healthcare, specifically in hospitals. Among the different factors as the major cost drivers are: prolonged hospital length to stay, cost of patient isolation and complications⁴. The treatment of MRSA infectious is complicated not only to their resistance to beta-lactam antibiotics, but also by their growing as biofilm. Microorganisms into biofilms become 1000 times more resistant than planktonic bacteria to physical and chemical attacks⁵. The tolerance of biofilms to antimicrobials increase with biofilm maturation and it is attributed mainly to restricted penetration of antibiotics, slow growth of pathogen microorganisms. Despite of their effectiveness, antibiotics more commonly employed on infectious diseases treatment are very expensive for most of patients, constituting a huge disadvantage during clinical practice in developing countries. It is urgent to develop new alternative drugs with antimicrobial and antibiofilm properties, non-antibiotic type, low cost and safe for treating infectious diseases. To attend this challenge of biofilms and their increased tolerance to antimicrobial agents, topical administration arises as an interesting alternative since it provides high local concentrations by delivering drugs directly to the site of infection and avoiding systemic side effects.




FIGURE 1.1

Staphylococcus aureus methicillin-resistant (MRSA) stained with SYTO9 green observed by fluorescent microscopy. Bar indicates 10 μ M.

Nanotechnology holds the promise of revolutionize modern medicine developing smart drugs with the ability to overcome biological barriers to efficiently get the target sites of diseases^{6,7}. The increase of multidrug resistance among pathogen microorganisms to the common antibiotics force to use higher doses of antibiotics to effectively inhibit the bacterial growth. Nanocomposites have been shown antimicrobial activity against gram positive and gram negative bacteria. Nanostructures of several metals like; silver, gold, zinc, and titanium and bismuth have been described with very good results⁸⁻¹². However, most of them present high toxicity on human cells,

limiting their used¹³⁻¹⁶. Bismuth is considered as “green metal”, non-carcinogenic, and less bioaccumulative than other heavy metals like lead and antimony¹⁷. It is used in industry and for treatment of gastrointestinal diseases^{18,19}. Early reports of our group described antimicrobial and antibiofilm properties of bismuth lipophilic nanoparticles (BisBAL NPs; Figure 1.2) against oral pathogens including bacteria, fungus and parasites. The BisABL nanoparticles did not present cytotoxicity on epithelial and blood human cells²⁰⁻²⁴. These studies have been described that bismuth nanoparticles inhibit *Streptococcus mutans* growth at concentrations lower than 1 mM and bismuth oxide nanoparticles exhibited antifungal activity on *Candida albicans* since 2 mM, showing better results than commercial antifungals.

More recently bismuth nanoparticles synthesis was modified adding the reaction with 2,3-dimercapto-1-propanol (BAL), developing the BisBAL nanoparticles with lipophilic property. The antimicrobial activity of these nanostructures increased 1000 times in comparison with our previous synthesis and may due their lipophilic attribute. When the antimicrobial activity was studied, the results showed MICs values of 5-10 μM to inhibit oral bacterial and fungal growth. BisBAL NPs compete in efficacy against most common antibiotics. Despite of antimicrobial and antibiofilm properties of BisBAL NPs seems to be interesting, their effect of BisBAL nanoparticles against multidrug resistant pathogens (like MRSA) has not been explored. Will be interesting to develop a pharmaceutical presentation with BisBAL NPs as active ingredient and demonstrate their clinical application. Since infectious diseases initiate in specific sites on human body, they can be treating locally. Therefore we developed a hydrogel loaded with BisBAL nanoparticles and evaluated their potential as antimicrobial agent. MRSA was used as target to determine their possible clinical application as alternative treatment of infectious diseases.




FIGURE 1.2

i) Bismuth lipophilic nanoparticles (BisBAL NPs) observed by Scanning Electron Microscopy (SEM). ii) EDS spectrum showed the element composition in the sample observed by SEM. iii) The bismuth presence in the sample of BisBAL nanoparticles was identified by X-ray diffraction pattern. iv) The UV-Bis absorbance.

In this work is described the effectiveness of a BisBAL NPs-Gel to detach Methicillin-resistant *Staphylococcus aureus* biofilm. $6\mu\text{M}$ was the MIC of BisBAL nanoparticles necessary to inhibit the MRSA growth competing in efficacy with most common antibiotics. A 24h MRSA biofilm was detached from 96-well plate and bone surface after exposition to BisBAL NPs-Gel for 24h supporting the bactericidal findings. Finally, bismuth lipophilic nanoparticles showed not cytotoxicity on human gingival fibroblasts, suggesting the lack of non-desired effects. Altogether these results suggest BisBAL nanoparticles are a low cost and safe alternative to fight against MRSA infections.

Antimicrobial and antibiofilm activities of BisBAL NPs-Gel on MRSA

BisBAL nanoparticles were synthesized and characterized as early was described in our recent publications²². To obtain the BisBAL NPs gel, 50 mL of sterile distilled water were heated until 70°C and slowly 0.5 g of carbopol (Sigma Aldrich, MO, USA) were mixture with magnetic agitation. Following 2 mL of BisBAL nanoparticles were added to get a final concentration of $100\mu\text{M}$. Finally, 500 μL of triethanolamine (TEA; Sigma Aldrich, MO, USA) were added to the solution and employing more sterile water to get a final volume of 100 mL. Under these experimental conditions, the BisBAL NPs-Gel obtained a final concentration of $100\mu\text{M}$. The characterization of BisBAL NPs-Gel was made by Scanning Electron Microscopy (SEM), EDS spectrum, XRD and UV-visible absorption spectra to confirm the identity of bismuth (Figure 1.2 i-iv).

A general description of methodology followed to determine the antimicrobial and antibiofilm activities of BisBAL NPs-Gel is showed in Figure 1.3. The antimicrobial activity of BisBAL NPs-Gel on Methicillin-resistant *Staphylococcus aureus* growth (ATCC no 33592) was determined using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Biotium, Hayward, CA)^{25,26} according to the instructions of manufacturer. Briefly, 1×10^4 MRSA cells were inoculated in 100 μL of trypticasesoybroth (TSB) medium in a 96-well polystyreneplate. Three wells with only TSB medium were used as MRSA growing control. 0.39-125 μM of BisBAL NPs-Gel were added to interfere with bacterial growth. As positive control 10 μM of Doxycycline was employed. The 96-well plate was incubated at 37°C overnight. 10 μL of MTT was added to each well, the plate was protected against light and incubated at 37°C for 2h. 200 μL of Dimethylsulfoxide (DMSO; Sigma Aldrich, MO, USA) was added to dissolve the reduced MTT. The number of live cells was determined by a Microplate Absorbance Reader (Biorad, Philadelphia, PA) at 595 nm. The experiment was repeated three times and the measured optical density were analyzed by descriptive statistics.

Based on the protocol described above, the antibiofilm property of BisBAL NPs-Gel was analyzed. A 24h MRSA biofilm on 96-well plate or bone surface was exposed to $100\mu\text{M}$ BisBAL NPs-Gel or 10 μM of Doxycycline for 24h a 37°C . MRSA biofilm remains was washed three times with PBS and stained with FDA. The bacterial biofilm was observed under fluorescence microscopy at 495 nm (Thornwood, NY). The images were analyzed by using Axio Vision software (Thornwood, NY). The fluorescence intensity was measured using a 96-well scanning fluorometer Glomax[®] Multi + Microplate Multimode (Promega, Madison, WI) at wavelength of 525 nm.

Effect of BisBAL NPs-Gel on MRSA biofilm on bone surface




FIGURE 1.3

Graphical abstract to determine the antimicrobial and antibiofilm activities of a BisBAL-NPs-Gel on MRSA biofilm.

To explore the possible cytotoxic effect of BisBAL NPs-Gel on Human Gingival Fibroblasts (HGFs), cells were cultivated in Dulbecco's modified Eagle's medium (DMEM)/Ham's F12 (DMEM/F12) supplemented with 10% fetal bovine serum (FBS) (Gibco-Invitrogen, Carlsbad, California, USA) and 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B (Sigma-Aldrich Corporation, St. Louis, MO) at 37 °C and 5% CO₂²⁷. After obtaining cell confluence, BisBAL nanoparticles were added at a final concentration of 1000-5 µM. Cells were maintained in growth medium for 24h. After that the medium was removed and cells were washed with phosphate buffered saline (PBS). The cell viability was measured by Fluorescein Diacetate assay (FDA, Sigma-Aldrich Corporation, St. Louis, MO). Data were analyzed to determine the number of viable cells.

Characterization of the BisBAL NPs-Gel by SEM

The BisBAL NPs-Gel showed a cluster of donut shape with an electro dense core of BisBAL nanoparticles visualized by SEM. The average size of each donut was of 145.6 nm in diameter

(Figure 1.4i, ii and iii). Bismuth composition was corroborated inside of SEM images by EDS spectrum (Figure 1.4iv). The BisBAL nanoparticles synthesized by colloidal method were used as active ingredient to develop a hydrogel and it was stable to room temperature for until 3 months. Since early it was described the antimicrobial activity of BisBAL nanoparticles we corroborate this property in the hydrogel composite BisBAL-NPs-Gel against MRSA growth. Following a deep characterization of the bactericidal activity of BisBAL-NPs-Gel against MRSA was made to compare their efficacy with most common antibiotics like Doxycycline. The bismuth NPs hydrogel will have the advantage of being non-antibiotic type with a lower cost of synthesis in comparison with antibiotics.





FIGURE 1.4

Characterization of the hydrogel of Bismuth Lipophilic (BisBAL) Nanoparticles by Scanning Electron Microscopy (SEM).

Determination of MIC of BisBAL NPs-Gel on MRSA growth

When Minimal Inhibitory Concentration (MIC) of BisBAL NPs-Gel was evaluated to interfere with MRSA growth, 125 μM of BisBAL NPs showed the higher inhibition of bacterial growth, leading to 20 μM of Doxycycline as can be seen in the Figure 1.5. The MIC was established in 6 μM of BisBAL NPs as the minimal amount of bismuth nanoparticles gel to block the MRSA growth.

Early reports have been described high antimicrobial activity against MRSA growth using gold and selenium nanoparticles with an apparent low cytotoxicity on mammalian cells^{28,29}. Our findings are agreed with these reports supporting the hypothesis that nanotherapeutics is an innovative way to control MRSA infections.

**FIGURE 1.5**


Minimal Inhibitory Concentration (MIC) of BisBAL nanoparticles against Methicillin-resistant *Staphylococcus aureus* growth.

The action mechanism of BisBAL nanoparticles to inhibit the bacterial growth is not well established. Our hypothesis is that bismuth nanoparticles alter the cellular membrane affecting their permeability leading to lysis. This hypothesis is based on early experiments using Calcein AM assays. Calcein AM is a non-fluorescent, hydrophobic compound that easily permeates intact, live cells. The hydrolysis of Calcein AM by intracellular esterases produces calcein, a hydrophilic strongly fluorescent compound that is well-retained in the cell cytoplasm. Maybe BisBAL NPs through their lipophilic property have affinity for cell membrane, penetrating to the cell cytoplasm and breaking down membrane structure. By the other side, we do not have evidence of damage on cell genome or inhibition of protein synthesis after exposition to bismuth nanoparticles.


Antibiofilm activity of BisBAL NPs-Gel on MRSA biofilm

When antibiofilm activity of BisBAL NPs-gel was explored, results showed that 100 μM BisBAL NPs-Gel detached 79% of MRSA biofilm, while Doxycycline removed 86% of cells in comparison with the growing control. Identical results were obtained on MRSA biofilm on boon surface. These results suggest that BisBAL NPs-Gel is as effective as Doxycycline to detach Methicillin-resistant *S. aureus* biofilm (Figure 1.6). Agarwala *et al* reported in 2014 that Copper oxide nanoparticles exhibited antibiofilm and bactericidal properties against MRSA in a dose dependent, however their cytotoxicity on mammalian cells was not explored³⁰.

A)



B)



C)




FIGURE 1.6

Antibiofilm activity of BisBAL-NPs-Gel against MRSA *S. aureus* biofilm by fluorescence microscopy.

Cytotoxicity of BisBAL NPs-Gel on Human Gingival Fibroblasts (HGFs)

When cytotoxic effect of BisBAL NPs-Gel was analyzed on HGFs, results show that 100 μM of BisBAL NPs-Gel decrease only 16% of cell viability after 24h of treatment in comparison with the growing control (Figure 1.7). Previous studies have been described antimicrobial properties of several metals like; silver, gold, zinc, and titanium with very good results⁸⁻¹². However, most of them present high toxicity on human cells, limiting their use in clinical practice¹³⁻¹⁶. Our result is very important because it means that BisBAL NPs-Gel can be used at a final concentration of 100 μM as antimicrobial and antibiofilm drug against MRSA without affecting mammalian cells. It is important to mention that bacterial and eukaryotic cells have important differences that may explain why BisBAL nanoparticles inhibit bacterial growth without affecting human cells. First of all, bacteria are around 10 times smaller than human cells. Following the hypothesis described above, if BisBAL NPs attach to the cell membrane to penetrate to the cytoplasm, altering their permeability, a human cell will require a higher quantity of BisBAL nanoparticles than a bacterial one to get the same effect. This phenomenon will explain the obtained data using 250-1000 μM of BisBAL NPs killing the human gingival fibroblast but remaining cell viability when 5-100 μM of BisBAL NPs were added to cell cultures. This hypothesis is supported by early experiments adding BisBAL nanoparticles to *Trichomonas vaginalis* culture. These parasites have a size similar to eukaryotic cells. 500 μM of BisBAL NPs were required to inhibit parasitic growth³¹ in comparison with 60-100 μM to block the growing of MRSA.

Cytotoxic effect of BisBAL NPs-Gel on Human Gingival Fibroblasts




FIGURE 1.7

Cytotoxicity of the hydrogel of BisBAL Nanoparticles on Human Gingival Fibroblasts (HGFs).

Conclusion

Bismuth lipophilic nanoparticles as active ingredient of a hydrogel inhibit the MRSA growth since a

final concentration of 6 μM . 100 μM of BisBAL NPs-Gel detached the bacterial biofilm on dentin model suggesting that BisBAL nanoparticles hydrogel is a non-antibiotic, low cost and safe alternative to fight against MRSA infections. Applied in a topic manner, the BisBAL NPs-Gel provides high local concentrations by delivering bismuth nanoparticles directly to the site of infection avoiding side effects.

Acknowledgements

Authors wish to thank to Nayeli Pineda-Aguilar from CIMAV-Monterrey for their technical assistance in scanning electron microscopy. Claudio Cabral-Romero wants to thanks to CONACyT for financing the project 183825.

References

1. Tacconelli E, Venkataraman L, De Girolami PC, EM DA. Methicillin-resistant *Staphylococcus aureus* bacteraemia diagnosed at hospital admission: distinguishing between community-acquired versus healthcare-associated strains. *The Journal of antimicrobial chemotherapy*. Mar 2004;53(3):474-479.
2. Ito T, Katayama Y, Asada K, et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant *Staphylococcus aureus*. *Antimicrobial agents and chemotherapy*. May 2001;45(5):1323-1336.
3. Peyrani P, Allen M, Seligson D, et al. Clinical outcomes of osteomyelitis patients infected with methicillin-resistant *Staphylococcus aureus* USA-300 strains. *American journal of orthopedics (Belle Mead, N.J.)*. Mar 2012;41(3):117-122.
4. Kock R, Becker K, Cookson B, et al. Methicillin-resistant *Staphylococcus aureus* (MRSA): burden of disease and control challenges in Europe. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. Oct 14 2010;15(41):19688.
5. Nickel JC, Wright JB, Ruseska I, Marrie TJ, Whitfield C, Costerton JW. Antibiotic resistance of *Pseudomonas aeruginosa* colonizing a urinary catheter in vitro. *European journal of clinical microbiology*. Apr 1985;4(2):213-218.
6. Desai N. Challenges in development of nanoparticle-based therapeutics. *The AAPS journal*. Jun 2012;14(2):282-295.
7. Nalwa HS. Encyclopedia of Nanoscience and Nanotechnology. In: Nalwa HS, ed. Vol 1-10. Los Angeles, CA American Scientific Publishers; 2004.
8. Kim JS, Kuk E, Yu KN, et al. Antimicrobial effects of silver nanoparticles. *Nanomedicine : nanotechnology, biology, and medicine*. Mar 2007;3(1):95-101.
9. Huang WC, Tsai PJ, Chen YC. Functional gold nanoparticles as photothermal agents for selective-killing of pathogenic bacteria. *Nanomedicine (London, England)*. Dec 2007;2(6):777-787.
10. Castillo-Martínez JC, et al. Antibacterial and Antibiofilm Activities of the Photothermal Therapy Using Gold Nanorods against Seven Different Bacterial Strains. *Journal of Nanomaterials*. 2015;2015:7.

11. Hsueh YH, Ke WJ, Hsieh CT, Lin KS, Tzou DY, Chiang CL. ZnO Nanoparticles Affect *Bacillus subtilis* Cell Growth and Biofilm Formation. *PLoS one*. 2015;10(6):e0128457.
12. Nataraj N, Anjusree GS, Madhavan AA, et al. Synthesis and anti-staphylococcal activity of TiO₂ nanoparticles and nanowires in ex vivo porcine skin model. *Journal of biomedical nanotechnology*. May 2014;10(5):864-870.
13. Gaillet S, Rouanet JM. Silver nanoparticles: their potential toxic effects after oral exposure and underlying mechanisms--a review. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. Mar 2015;77:58-63.
14. Favi PM, Gao M, Johana Sepulveda Arango L, et al. Shape and surface effects on the cytotoxicity of nanoparticles: Gold nanospheres versus gold nanostars. *Journal of biomedical materials research. Part A*. Apr 22 2015.
15. Czajka M, Sawicki K, Sikorska K, Popek S, Kruszewski M, Kapka-Skrzypczak L. Toxicity of titanium dioxide nanoparticles in central nervous system. *Toxicology in vitro : an international journal published in association with BIBRA*. Aug 2015;29(5):1042-1052.
16. Chen TH, Lin CC, Meng PJ. Zinc oxide nanoparticles alter hatching and larval locomotor activity in zebrafish (*Danio rerio*). *Journal of hazardous materials*. Jul 30 2014;277:134-140.
17. Norman NC. *Chemistry of Arsenic, Antimony, and Bismuth*. UK: Blackie Academic and Professional; 1998.
18. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. *The Cochrane database of systematic reviews*. 2006(4):CD001960.
19. Adamian ZN, Abovian HV, Aroutiounian VM. Smoke sensor on the base of Bi₂O₃ sesquioxide. *Sensors and Actuators B: Chemical*. 1996;35(1-3):241-243.
20. Hernandez-Delgadillo R, Velasco-Arias D, Diaz D, et al. Zerovalent bismuth nanoparticles inhibit *Streptococcus mutans* growth and formation of biofilm. *International journal of nanomedicine*. 2012;7:2109-2113.
21. Hernandez-Delgadillo R, Velasco-Arias D, Martinez-Sanmiguel JJ, et al. Bismuth oxide aqueous colloidal nanoparticles inhibit *Candida albicans* growth and biofilm formation. *International journal of nanomedicine*. 2013;8:1645-1652.
22. Appala Raju Badireddy SC, Rene Hernandez-Delgadillo, Rosa Isela Sánchez-Nájera and Claudio Cabral-Romero Synthesis and characterization of lipophilic bismuth dimercaptopropanol nanoparticles and their effects on oral microorganisms growth and biofilm formation. *Journal of Nanoparticle Research*. 2014,16:2456.
23. Hernandez-Delgadillo R, Badireddy AR, Zaragoza-Maga, et al. Effect of Lipophilic Bismuth Nanoparticles on Erythrocytes. *Journal of Nanomaterials*. 2015;2015:9.
24. Hernandez-Delgadillo R ARBM-SJ, Contreras-Cordero J F, Martinez-Gonzalez G I, Sánchez-Nájera R I, Chellam S, and Cabral-Romero Claudio. Cytotoxic Effect of Lipophilic Bismuth Dimercaptopropanol Nanoparticles on Epithelial Cells *Journal of Nanoscience and Nanotechnology*. 2016;2016(1):203-209.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Journal of immunological methods*. Dec 16 1983;65(1-2):55-63.
26. Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. *Journal of neurochemistry*. Aug 1997;69(2):581-593.

27. Carmona-Rodríguez B, Alvarez-Perez MA, Narayanan AS, et al. Human Cementum Protein 1 induces expression of bone and cementum proteins by human gingival fibroblasts. *Biochemical and biophysical research communications*. Jul 6 2007;358(3):763-769.
28. Li X, Robinson SM, Gupta A, et al. Functional gold nanoparticles as potent antimicrobial agents against multi-drug-resistant bacteria. *ACS nano*. Oct 28 2014;8(10):10682-10686.
29. Huang X, Chen X, Chen Q, Yu Q, Sun D, Liu J. Investigation of functional selenium nanoparticles as potent antimicrobial agents against superbugs. *Acta biomaterialia*. Jan 15 2016;30:397-407.
30. Agarwala M, Choudhury B, Yadav RN. Comparative study of antibiofilm activity of copper oxide and iron oxide nanoparticles against multidrug resistant biofilm forming uropathogens. *Indian journal of microbiology*. Sep 2014;54(3):365-368.
31. Rodríguez-Luis OE, Hernández-Delgadillo R, Pineda- Aguilar, et al., Effect of Bismuth Lipophilic Nanoparticles (BisBAL NPs) on *Trichomonas vaginalis* Growth. *Journal of Nanoscience and Nanotechnology*. 2016;17: 4618- 4622.